AIM ImmunoTech (AIM) Other Non-Current Liabilities (2010 - 2025)
AIM ImmunoTech's (AIM) quarterly Other Non-Current Liabilities came in at $8.2 million in Q4 2025, up 12.9% on a QoQ basis from $7.3 million in Q3 2025.
AIM ImmunoTech (AIM) Other Non-Current Liabilities (2010 - 2025) Analysis & Trends
AIM ImmunoTech (AIM) has 13 years of Other Non-Current Liabilities data on file, last reported at $8.2 million in Q4 2025.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $8.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.2 million (changed N/A YoY) and the FY2025 annual result came in at $8.2 million, changed N/A from the prior year.
- Other Non-Current Liabilities grew to $8.2 million in Q4 2025, from $7.3 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $8.2 million in Q4 2025 to a low of $1000.0 in Q2 2022.
- A 3-year average of $2.0 million and a median of $183500.0 in 2021 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities gained 0.97% — and 2022, when it sank 99.52%.
- Tracing AIM's Other Non-Current Liabilities over 3 years: stood at $35000.0 in 2021, then sank by 97.14% to $1000.0 in 2022, then jumped by 824300.0% to $8.2 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $8.2 million (Q4 2025), $7.3 million (Q3 2025), and $1000.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.24 Mn |
| Sep 30, 2025 | 7.30 Mn |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 4,000.00 |
| Dec 31, 2021 | 35,000.00 |
| Sep 30, 2021 | 158,000.00 |
| Jun 30, 2021 | 209,000.00 |
| Mar 31, 2021 | 217,000.00 |
| Dec 31, 2020 | 180,000.00 |
| Sep 30, 2020 | 177,000.00 |
| Jun 30, 2020 | 207,000.00 |
| Mar 31, 2020 | 239,000.00 |
| Dec 31, 2019 | 57,000.00 |
| Sep 30, 2019 | 82,000.00 |
| Jun 30, 2019 | 874,000.00 |
| Mar 31, 2019 | 3.90 Mn |
| Dec 31, 2018 | 1.06 Mn |
| Sep 30, 2018 | 1.40 Mn |
| Jun 30, 2018 | 2.10 Mn |
| Mar 31, 2018 | 971,000.00 |